Skip to main content
. Author manuscript; available in PMC: 2018 Feb 13.
Published in final edited form as: J Neuroimmunol. 2012 Feb 18;245(1-2):8–14. doi: 10.1016/j.jneuroim.2012.01.007

TABLE I. EAE in Cx43 and Cx30 deficient mice.

Genotype n AUCa Peak Score Date of Onset Date of Peak Score Incidence (%)
Mean SE Mean SE Mean SE Mean SE Mean SE
WT 27 16.8 1.4 2.5 0.1 12.6 0.5 15.1 0.6 81.6 4.4
Cx43F/F Cx30+/+ 21 18.0 1.8 2.8 0.1 12.7 0.7 15.4 0.8 91.6 5.3
Cre Cx43F/F (sKO) 26 19.7 1.1 3.0 0.1 12.6 0.5 15.3 0.5 91.6 5.2
Cx43F/F Cx30−/− 10 13.2 1.2 2.3 0.2 12.7 0.7 16.9 1.0 100.0 5.2
Cre Cx43F/F Cx30−/− (dKO) 16 16.8 1.9 2.7 0.2 12.6 0.5 15.8 0.7 83.6 7.5
a

Area under the curve (AUC) was calculated for days 10-25. Animals were excluded from analysis which did not attain a clinical score of at least 1 for two consecutive days, or which died or were sacrificed before 25 days post immunization. n, number of animals per group included in analysis. SE, standard error.